Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-707 as first-line treatment for metastatic colorectal cancer
CTR20242357Phase 2Active
- Sponsor
- 3SBio
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in colorectal cancer (CRC), sponsored by 3SBio. Started Sep 2024; status: active.
02
Drugs
PF-08634404
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20242357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242357.